Skip to main content
. Author manuscript; available in PMC: 2013 Jan 1.
Published in final edited form as: Antiviral Res. 2011 Nov 29;93(1):204–208. doi: 10.1016/j.antiviral.2011.11.013

Figure 2.

Figure 2

Clinical signs after experimental infection with aerosolized RPXV. (A) Variation of body weight. (B) Variation of body temperature. Absent markers denote missing data. Significant differences (P<0.05) from untreated controls are denoted by hollow markers. Error bars are standard error.